Ayrton Capital reports 9.72% Genprex stake on 13G
Genprex, Inc. received a Schedule 13G showing that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri together report beneficial ownership of 249,788 shares of Genprex common stock through warrants.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Genprex, Inc. received a Schedule 13G showing that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri together report beneficial ownership of 249,788 shares of Genprex common stock through warrants. This position represents 9.72% of the common stock, calculated using 2,318,894 shares outstanding as of November 19, 2025, plus the warrant shares. The warrants are subject to a 9.99% beneficial ownership blocker, limiting how many shares can be issued on exercise at any time. The investors certify the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Genprex.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Genprex (GNPX) is reported in this Schedule 13G?
Who are the reporting persons in the Genprex (GNPX) Schedule 13G?
How is the 9.72% Genprex (GNPX) ownership by Ayrton Capital and affiliates calculated?
What securities do Ayrton Capital and Alto Opportunity Master Fund hold in Genprex (GNPX)?
What is the 9.99% beneficial ownership blocker mentioned for Genprex (GNPX)?
Are Ayrton Capital and its affiliates seeking control of Genprex (GNPX)?
AI-generated analysis. How Rhea-AI works. Not financial advice.